reports
- Damien Choplain
- Martial Descoutures
Novartis : Excellent T1 justifiant un relèvement de guidance FY
>T1 au-dessus des attentes sur la topline (+4%) et la bottom line (+7%) - Le T1 ressort au-dessus des attentes au niveau des ventes (+4% vs Css) et du core BPA (+7% vs Css). Les ventes progressent de 11% tcc (10% en publié) tirées par tous les produits phares : Entresto (34%, +15% vs Css), Cosentyx (23%, 10% vs Css), Kisqali (51%, -2% vs Css) et Kesimpta (66%, 0% vs Css). Notons que Pluvicto (47%, -3% vs Css) ressort une nouvelle fois légèrement en dessous des attente...
Sous l’effet de la montée en puissance de son pipeline d’opérations, I...
Sous l’effet de la montée en puissance de son pipeline d’opérations, INEA enregistre une croissance de son chiffre d’affaires de 22% au T1 2024 Paris, le 23 avril 2024 INEA (ISIN : FR0010341032), spécialiste de l’immobilier tertiaire en Régions et leader du Green Building, annonce aujourd’hui son chiffre d’affaires consolidé pour le 1er trimestre, clos le 31 mars 2024. En M€ T1 2024 T1 2023 Variation Revenus locatifs bruts consolidé (IFRS) 18,8 15,5 + 22% dont à périmètre constant 16,4 14,9 + 10% Le chiffre d’affaires d’INEA au 1er trimestre 2024 s’élève à 18,8 M€...
- ABGSC Financials Research
- Jan Erik Gjerland
- Patrik Brattelius
- ABGSC Credit Research
- Glenn Kringhaug
- Nicolas David
SAP : A good start to the year, but not enough (and too early) to rais...
>Solid Cloud & Software revenue, driven by on-premises resilience. Strong CCB - SAP released its Q1 2024 earnings yesterday after market. Sales were just in line, at € 8.04bn (css: € 8.02bn) but Cloud & Software revenue growth on cc came in at 11%, above expectations (css: 9% cc), thanks, again, to impressive resilience from the Support revenues (-1% cc vs css: -2.8% cc), while Cloud revenue growth was just in line with expectations (25% cc). The current Cloud backlo...
- Russell Waller
EQS-News: Mayr-Melnhof Karton AG: MM reports first quarter 2024 result...
EQS-News: Mayr-Melnhof Karton AG / Key word(s): Quarter Results Mayr-Melnhof Karton AG: MM reports first quarter 2024 results 23.04.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. Result below previous year as expected Significant volume growth at MM Board & Paper Continuity at a good level at MM Packaging Weak consumption continues to weigh on end markets Pressure on margins carries on Successful profit & cash protection programme will be continued Sales price development decisive for earnings situation in 2024 Group Key...
EQS-News: Mayr-Melnhof Karton AG: MM veröffentlicht Ergebnisse zum 1. ...
EQS-News: Mayr-Melnhof Karton AG / Schlagwort(e): Quartalsergebnis Mayr-Melnhof Karton AG: MM veröffentlicht Ergebnisse zum 1. Quartal 2024 23.04.2024 / 08:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Ergebnis erwartungsgemäß unter Vorjahr Deutlicher Mengenzuwachs bei MM Board & Paper Kontinuität auf gutem Niveau bei MM Packaging Konsumschwäche belastet weiterhin Endmärkte Margendruck hält an Erfolgreiches Profit & Cash Protection-Programm wird fortgesetzt Verkaufspreisentwicklung für Ergebnissituation 2024 entscheidend Ke...
- Chris Hoare
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Olof Cederholm
- Andy Hanson
Topps Group (TPT LN) - Initiation: Market leader trading at cyclical l...
Topps Group is the UK’s largest specialist supplier and distributor of tiles and associated products to the UK’s domestic and commercial markets. Each of the last three years the Group has successfully achieved record revenue in a market that’s seen recent volume declines and regional peers enter administration. Following the right sizing of its business, Topps Group is now well positioned to capitalise on the economic recovery and continue taking share from competitors, supported by its global ...
- Chris Hoare
Rakuten (Reduce, TP: ¥400, -47%) Not on track to hit breakeven targets
Rakuten has seen stronger customer growth recently. In this note, we analyse whether Rakuten is on track to hit its target 8-10m customers and ¥2,500-3,000 ARPU by year end, and what this means for Rakuten’s target EBITDA breakeven by Dec 2024.
EQS-News: OHB SE: Konzernabschluss 2023
EQS-News: OHB SE / Schlagwort(e): Jahresergebnis OHB SE: Konzernabschluss 2023 23.04.2024 / 08:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. OHB SE: Konzernabschluss 2023 Gesamtleistung erreicht EUR 1.183 Mio. Dividendenvorschlag beträgt EUR 0,60 Freiwilliges öffentliches Übernahmeangebot schreitet planmäßig voran Der OHB-Konzern (ISIN: DE0005936124, Prime Standard) erreichte im Geschäftsjahr 2023 eine Gesamtleistung von EUR 1.182,8 Mio. (Vorjahr: EUR 1.001,3 Mio.), der Umsatz veränderte sich auf EUR 1.047,8 Mio. (Vorjahr: EUR...
Cairn Homes Plc: Transaction in Own Shares
Cairn Homes Plc (CRN) Cairn Homes Plc: Transaction in Own Shares 23-Apr-2024 / 07:00 GMT/BST 23 April 2024 Cairn Homes plc (the “Company”) Transaction in own shares The Company announces that on 22nd of April 2024 it purchased a total of 95,711 of its ordinary shares of EUR 0.001 each (the "ordinary shares") on Euronext Dublin and the London Stock Exchange through the Company's broker Goodbody Stockbrokers UC (“Goodbody”), as detailed below. The repurchased shares will be cancelled. Euronext Dublin London Stock Exchange Number o...
EQS-News: OHB SE: Consolidated financial statements 2023
EQS-News: OHB SE / Key word(s): Annual Results OHB SE: Consolidated financial statements 2023 23.04.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. OHB SE: Consolidated financial statements 2023 Total revenues reach EUR 1,183 million Dividend recommendation amounts to EUR 0.60 Voluntary public takeover offer progressing according to plan In fiscal year 2023, the OHB Group (ISIN: DE0005936124, Prime Standard) generated total revenues of EUR 1,182.8 (previous year: EUR 1,001.3 million), while sales changed to EUR 1,047.8 milli...
EQS-News: DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTEN...
EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION 23.04.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. Vancouver, BC, Canada, April 23rd, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that its second-generation ARMTM anti-cancer vaccine using ...
EQS-News: Screening completed: Berlin Cures achieves key milestone in ...
Issuer: Berlin Cures Holding AG / Key word(s): Miscellaneous Screening completed: Berlin Cures achieves key milestone in BC 007 Phase II Trial for treatment of Long COVID 23.04.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, Germany, 23 April 2024 – Berlin Cures, a pioneering clinical-stage biotechnology company, today announced the successful completion of patient screening for its pan-European Phase II trial of BC 007 (Rovunaptabin), a novel therapeutic candidate for the treatment of Long COVID. The study has now recr...
Full year trading update and notice of results
Molten Ventures Plc (GROW; GRW) Full year trading update and notice of results 23-Apr-2024 / 07:00 GMT/BST 23 April 2024 Molten Ventures plc ("Molten Ventures", "Molten", or the “Group”) Full year trading update and notice of results Stable and enhanced platform, in an improving market with greater expectation for realisations Molten Ventures (LSE: GROW, Euronext Dublin: GRW), a leading venture capital firm investing in and developing high-growth digital technology businesses, today announces an update on its portfolio, NAV (unaudited) and highlights for the year ...
EQS-News: ekrutierung abgeschlossen: Berlin Cures erreicht wichtigen M...
Emittent / Herausgeber: Berlin Cures Holding AG / Schlagwort(e): Sonstiges ekrutierung abgeschlossen: Berlin Cures erreicht wichtigen Meilenstein in der Phase-II-Studie mit BC 007 zur Behandlung von Long COVID 23.04.2024 / 08:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Berlin, 23. April 2024 – Berlin Cures, ein Biotechnologieunternehmen in der klinischen Phase, hat heute den erfolgreichen Abschluss der Patientenrekrutierung für seine europaweite Phase-II-Studie mit BC 007 (Rovunaptabin) bekanntgegeben. BC 007 ist Berlin Cures‘ ...
United Airlines Holdings Inc: 1 director
A director at United Airlines Holdings Inc sold 30,000 shares at 50.843USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.